21. Participation in other studi es involving investigational drug(s) within 4 weeks prior to study entry . 22.Known or suspected h ypersensitivity to an y of the VBIR -2 components. 23.Other acute or chronic medical or ps ychiatric condition, including recent (within the past y ear) or active suic idal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 74judgment of the investigator, would make the participant inappropriate for entry into this study . 24.COVID -19/SARS -CoV2: SARS -CoV2 testing is not mandated for entry into this protocol. However, testing should follow local clinical practice standards and requirements. A positive result on an approved test, even if the participant is asymptomatic, excludes a participant from this trial. 25.Investigator site staff members directl y involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are Pfizer emplo yees, including their famil y members, directly involved in the conduct of the study . 26.Fertile male participants and female participants of childbearing potential who are unwilling or unable to use 2 highl y effe ctive methods of contraception as outlined in this protocol for the duration of the study and for at least 5 months after the last dose of investigational product [per Section 4.3 below] . 4.3.Lifestyle Requirements (Part 1 and Part 2) The investigator or his or her designee, in consultation with the participant, will confirm that the participant has selected an appropriate method of contraception for the individual participant [and his or her partner(s)] from the permitted list of contr aception methods (see list below) and will confirm that the participant has been instructed in its consistent and correct use. At time points indicated in the Schedule of Activities, the investigator or designee will inform the participant of the need to use 2 highl y effective methods of contraception consistently and correctly and document the conversation, and the participant’s affirmation, in the participant’s chart. In addition, the investigator or designee will instruct the participant to call immediately if 1 or both of the selected contraception methods is discontinued or if pregnancy is known or suspected in the participant or partner. In addition, the investigator or designee will instruct the participant to call immed iately if the selected contraception method is discontinued or if pregnancy is known or suspected in the participant or partner. Highl y effective methods of contraception are those that, alone or in combination, result in a failure rate of less than 1% pe r year when used consistently and correctly (ie, perfect use) and include: 1.Correctly placed copper -containing intrauterine device (IUD). 2.Male condom or female condom used WI TH a spermicide (ie, foam, gel, film, cream, or suppository ). For countries where spermicide is not available or condom plus spermicide is not accepted as highl y effective contraception, this option is not appropriate. 3.Male sterilization with absence of sperm in the postvasectomy ejaculate. PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 754.Bilateral tubal ligation/ bilateral salpingec tomy or bilateral tubal occlusive procedure (provided that occlusion has been confirmed in accordance with the device’s label). a.All sexually active male participants must agree to prevent potential transfer to and exposure of partner(s) to drug through eja culate by using a condom consistently and correctly , beginning with the first dose of investigational product and continuing for; at least 5 months after the last dose of [investigational product OR comedication]. 4.4.Sponsor’s Qualified Medical Personnel The contact information for the sponsor’s appropriately qualified medical personnel for the study is documented in the study contact list located in the supporting Study Manual and in the team SharePoint Site. To facilitate access to appropriatel y qualified me dical personnel on study -related medical questions or problems, participant s are provided with a n Emergency Contact Card(ECC) . The ECC contains, at a minimum, (a) P rotocol and investigational product identifiers ;(b) Participant study numbers; (c) At lea st 2 emergency phone numbers, active 24 hours/day , 7 days/week, all holiday s and weekends, providing a method to contact both the Principal Investigator and the Research Site; and (d) a Pfizer Call Center number. The ECC is to be used only by outside medi cal personnel, not involved in the research stud y, primarily as a means of contacting the Principal Investigator or Research Site related to the care of a stud y participant. The Pfizer Call Center information is to be used only in the event that, after ca lling the phone numbers of both the Principal Investigator and Research Site Staff, neither could not be reached in case of an Emergency . The ECC should be used only in the event that the established communication pathway s between the Principal Investigator, the Research site, and the Study Team are not available. Importantly , the ECC is intended to augment, and not to replace, the established communication pathways between the Principal Investigator, the Research site, and the Study Team for ad vice on medical issues arising during the study .The ECC is not intended for use by the participant directly ; if a participant calls the Pfizer Call Center directly , the participant will be directed back to the Principal Investigator or Research site. 5.STU DY TREATMENTS For the purposes of this study , and per International Conference on Harmonisation (I CH) guidelines, investigational product is defined as a pharmaceutical form of an active ingredient or placebo being tested or used as a reference/comparator in a clinical trial, including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved indication, or when used to gain further information about an approved use (I CH E6 1.33). PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 76For this study , the investigational product VBIR -2 (PF -06936308) consists of: Reagent PF # AdC68, an adenovirus prime vaccination PF-06871923 pDNA, aPlasmid DNA boost vaccination PF-06871925 Tremelimumab, an CTLA4 monoclonal antibody PF-06753388 Sasanlimab, an anti -PD-1 monoclonal antibody PF-06801591 5.1.Allocation to Treatment Eligible participants will be enrolled to receive components of VBIR -2 in an open -labeled, unblinded manner. In Part 1, participants will be successivel y assigned to the next available treatment slot at a dose level decided on after the previous cohort’s safet y evaluation and ongoing observations of earlier enrolled participants.